Nek­tar’s lat­est PhII flop threat­ens to un­rav­el $400M-plus deal with Eli Lil­ly

Eli Lil­ly is slam­ming the Phase III door for the lead pro­gram out of its six-year-old pact with Nek­tar Ther­a­peu­tics, af­ter their part­nered au­toim­mune drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.